Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in MAP2K1

*Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL

†Department of Pathology, University Hospital Campus Bio-Medico, Rome, Italy

‡Department of Pathology, Umeå University, Umeå, Sweden

§Institute for Dermatohistopathology, Pathology Institute Enge, Zürich, Switzerland

∥Division of Advanced Diagnostics, William Osler Health System, Brampton

¶Department of Laboratory Medicine and Pathology, University of Toronto

#Department of Laboratory Medicine, Lifelabs LP, Toronto, ON, Canada

M.F.-V. and M.H. contributed equally.

This study was approved by our Institutional Review Board (IRB) (STU00001127). Given the retrospective chart review design, a waiver of HIPPA authorization was granted for research purposes, and informed consent was not required for this study.

Conflicts of Interest and Source of Funding: Supported by the IDP Foundation. P.G. has served as a consultant for Castle Biosciences and has received an honorarium for this; he has also received royalties for textbooks from Elsevier. For the remaining authors none were declared.

Correspondence: Pedram Gerami, MD, Department of Dermatology, Northwestern University, 676 N. St. Clair Street, Suite 1765, Chicago, IL 60611 (e-mail: [email protected]).

留言 (0)

沒有登入
gif